Oxfendazole Induces Apoptosis in Ovarian Cancer Cells by Activating JNK/MAPK Pathway and Inducing Reactive Oxygen Species Generation

• Published in: Biological & pharmaceutical bulletin 2023/11/01, Vol.46(11), pp.1569-1575
• Main Authors: Chen, Yanya, Wen, Chuangyu, Zhong, Shulin, Huang, Lishan, Xiang, Yuting, Ou, Yijing, Li, Lin, Tang, Wenting, Zhou, Chuyu, Wu, Zhixi, Ye, Weibiao, Wu, Shuyi, Huang, Suran, Li, Zhongjun
• Format: Article
• Language: English
• Subjects: Acetylcysteine; Anthelmintic agents; Antitumor activity; Apoptosis; Benzimidazoles; c-Jun N-terminal kinase (JNK); c-Jun protein; Cancer therapies; Cell death; Cell proliferation; Chemotherapy; Cisplatin; Cytotoxicity; JNK protein; Kinases; MAP kinase; Non-small cell lung carcinoma; Ovarian cancer; Oxfendazole; Reactive oxygen species; Small cell lung carcinoma; Transcription factors; Tubulin
• ISSN: 0918-6158; 1347-5215
• DOI: 10.1248/bpb.b23-00349

Ovarian cancer (OC) is one of the most common and high mortality type of cancer among women worldwide. The majority of patients with OC respond to chemotherapy initially; however, most of them become resistant to chemotherapy and results in a high level of treatment failure in OC. Therefore, novel agents for the treatment of OC are urgently required. Benzimidazole anthelmintics might have the promising efficacy for cancer therapy as their selectively binding activity to β-tubulin. Recent study has shown that one of the benzimidazole anthelmintics oxfendazole inhibited cell growth of non-small cell lung cancer cells, revealing its anti-cancer activity; however, the pharmacological action and detailed mechanism underlying the effects of oxfendazole on OC cells remain unclear. Therefore, the present study investigated the cytotoxic effects of oxfendazole on OC cells. Our results demonstrated that oxfendazole significantly decreased the viability of OC cells. Oxfendazole inhibited the proliferation, induced G2/M phase arrest and apoptotic cell death in A2780 cells. The c-Jun N-terminal kinase (JNK)/mitogen-activated protein kinase (MAPK) pathway was activated and reactive oxygen species (ROS) generation was increased in OC cells treated with oxfendazole; oxfendazole-induced apoptosis was notably abrogated when co-treated with JNK inhibitor SP600125 and ROS scavenger N-acetyl-L-cysteine (NAC), indicating that JNK/MAPK pathway activation and ROS accumulation was associated with the oxfendazole-induced apoptosis of OC cells. Moreover, oxfendazole could also induce the proliferation inhibition and apoptosis of cisplatin resistant cells. Collectively, these results revealed that oxfendazole may serve as a potential therapeutic agent for the treatment of OC.